|
| Press Releases |
|
 |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| On 12 March 2026, China Medical System Holdings Limited is pleased to announce that its subsidiary, Dermavon Holdings Limited has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix(R)) (the "Product", marketed as Opzelura(R) in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. more info >> |
|
| Thursday, March 5, 2026 |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008") received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration ("NMPA") on 4 March 2026. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| more info >> |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China more info >> |
|
| Friday, January 30, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
| Wednesday, July 16, 2025 |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| more info >> |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC
Mar 19, 2026 15:15 HKT/SGT
|
|
|
MHI Thermal Systems Expands Lineup of Air-to-Water Heat Pumps for the European Market
Mar 19, 2026 15:14 JST
|
|
|
三菱商事、代表取締役の異動に関するお知らせ
Mar 19, 2026 14:05: JST
|
|
|
太平洋大道資本合夥公司旗下關聯方完成對 Care.com 的收購
Mar 19, 2026 14:00 HKT/SGT
|
|
|
太平洋大道资本合伙公司旗下关联方完成对 Care.com 的收购
Mar 19, 2026 14:00 HKT/SGT
|
|
|
Honda、インドの二輪車第二工場に生産ラインを新設し生産能力を拡大
Mar 19, 2026 13:45: JST
|
|
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 19, 2026 13:33 HKT/SGT
|
|
|
三菱重工サーマルシステムズ、欧州向けヒートポンプ式給湯暖房機のラインアップを拡充
Mar 19, 2026 13:30: JST
|
|
|
DENSO Invests in Next Core Technologies to Enhance Performance of Electric Vehicles
Mar 19, 2026 14:25 JST
|
|
|
NEC Completes Design of Equipment for Technology Demonstration Satellite Aimed at Creating Japan's First Optical Communication Satellite Constellation
Mar 19, 2026 11:05 JST
|
|
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 19, 2026 10:54 JST
|
|
|
Hitachi is recognized as one of the World's Most Ethical Companies(R) for a second consecutive year
Mar 19, 2026 10:41 JST
|
|
|
Aleen Inc. Insights: Exploring LOINC Standard to Enhance Wellness Data Consistency
Mar 18, 2026 23:40 HKT/SGT
|
|
|
Illuminance announces global expansion and launch of its international platform
Mar 18, 2026 23:20 HKT/SGT
|
|
|
COSCO SHIPPING Ports Announces 2025 Annual Results
Mar 18, 2026 18:36 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
